Document Detail


Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
MedLine Citation:
PMID:  17417986     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To study the potential effectiveness of tumor necrosis factor a (TNF-alpha) inhibitor treatment for pulmonary fibrosis associated with a collagen vascular disease, CVD (rheumatoid arthritis, RA and systemic sclerosis, SSc) refractory to conventional treatment. METHODS: Four patients (three men with RA, one woman with SSc) were treated with infliximab. All patients received 3mg/kgr of infliximab at intervals 0, 2 and 6 weeks, and then maintenance infusions every 8 weeks afterwards for at least a 12-month period. Patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. RESULTS: Treatment was well-tolerated from all patients. Pulmonary fibrosis remained stable during treatment in terms of symptoms, pulmonary function tests (PFTs) and High resolution computed tomography (HRCT) appearance. As expected, a clinical response was observed in joint symptoms in patients with RA as evaluated by the DAS28 (Disease Activity Score, the 28 joint version). CONCLUSION: This study suggests that inhibition of TNF-alpha with infliximab may stabilize the progression of pulmonary fibrosis associated with CVD. Prospective, controlled trials are necessary to determine the efficacy of infliximab in pulmonary fibrosis associated CVD.
Authors:
K M Antoniou; M Mamoulaki; K Malagari; H D Kritikos; D Bouros; N M Siafakas; D T Boumpas
Related Documents :
11752506 - Soluble hla class i antigens in serum and synovial fluid from patients with rheumatoid ...
8039226 - High incidence of renal artery stenosis in patients with coronary artery disease.
478186 - Genetic susceptibility to diabetes mellitus: the distribution of properdin factor b (bf...
8773316 - Dr4 subtypes and their molecular properties in a population-based study of swedish chil...
18940656 - Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels...
23422466 - Comparison of gait training versus cranial osteopathy in patients with parkinson's dise...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  25     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2007 Jan-Feb
Date Detail:
Created Date:  2007-04-09     Completed Date:  2007-04-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  23-8     Citation Subset:  IM    
Affiliation:
Department of Thoracic Medicine, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Voutes, Heraklion, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications
Female
Humans
Male
Middle Aged
Pulmonary Fibrosis / drug therapy*,  etiology,  radiography
Respiratory Function Tests
Scleroderma, Systemic / complications
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
Next Document:  Oxaceprol--a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional...